NEW ORLEANS, Dec. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 15, 2017 to file lead plaintiff applications in a securities class action lawsuit against Navient Corporation (Nasdaq:NAVI), if they purchased the Company’s securities between February 25, 2016 through October 4, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Navient investors should visit us at https://www.claimsfiler.com/cases/view-navient-corporation-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Navient and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 5, 2017, the Pennsylvania Attorney General announced a lawsuit against Navient for unfair and deceptive lending practices associated with the origination of subprime loans to high risk borrowers as well as guiding borrowers to payment postponement plans (thereby allowing loan interest to accumulate), rather than promoting income-based repayment plans.
On this news, the price of Navient’s shares plummeted $2.10 per share, or over 14%, from its previous closing price to close at $12.60 per share.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



